ABLYNX ANNOUNCES WARRANT EXERCISE
July 24 2017 - 1:00AM
REGULATED INFORMATION
GHENT, Belgium,
24 July 2017 - Ablynx [Euronext Brussels: ABLX;
OTC: ABYLY] today announced, in conformity with Title II of
the Law of 2 May 2007 and the Royal Decree of 14 February 2008,
that an additional 19.833 common shares have been issued by the
Company in exchange for €121.444 as the result of the exercise of
warrants.
As a result of this transaction,
Ablynx now has 61.153.032 shares outstanding.
The total number of rights
(warrants) to subscribe to not yet issued securities conferring
voting rights currently is 2.860.214 which equals the total number
of voting rights that may result from the exercise of these
warrants. Currently 1.000 convertible bonds are outstanding
entitling the holders thereof to 7.733.952 shares of the Company in
the aggregate, upon conversion of such convertible bonds.
About
Ablynx
Ablynx is a biopharmaceutical
company engaged in the development of Nanobodies, proprietary
therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with
some of the features of small-molecule drugs. Ablynx is dedicated
to creating new medicines which will make a real difference to
society. Today, the Company has more than 45 proprietary and
partnered programmes in development in various therapeutic areas
including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple
pharmaceutical companies including AbbVie; Boehringer Ingelheim;
Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA;
Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho
Pharmaceuticals. The Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more
information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media/analyst
relations
FTI Consulting:
Julia Phillips, Brett Pollard, Mo Noonan
t: +44 20 3727 1000
e: ablynx@fticonsulting.com
pdf version of the press
release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Ablynx via Globenewswire